Table of Content

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1 Chapter Overview
3.2. Overview of Cardiovascular Drug Delivery Devices
3.2.1. Types of Cardiovascular Drug Delivery Devices
3.2.1.1. Drug Eluting Stents (DES)
3.2.1.2. Drug Eluting Balloons (DEB)
3.3. Key Indications Targeted by Cardiovascular Drug Delivery Devices
3.3.1. Atherosclerosis
3.3.2. Heart Failure
3.3.3. In-Stent Restenosis
3.4. Potential Risks Associated with Drug Eluting Stents and Balloons
3.5. Recent Advancements Related to Cardiovascular Drug Delivery Devices
3.6. Concluding Remarks

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Novel Cardiovascular Drug Delivery Devices: Overall Market Landscape
4.2.1. Analysis by Type of Drug Eluted
4.2.2. Analysis by Stent Material
4.2.3. Analysis by Maximum Post Dilatation Limit
4.2.4. Analysis by Maximum and Minimum Stent Length
4.2.5. Analysis by Maximum and Minimum Stent Diameter
4.2.6. Analysis by Maximum Nominal Pressure
4.2.7. Analysis by Maximum Rated Burst Pressure
4.2.8. Analysis by Administered Drug Concentration
4.2.9. Analysis by Minimum Strut Thickness
4.3. Novel Cardiovascular Drug Delivery Devices: Developers Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Leading Players: Analysis by Number of Products

5. KEY INSIGHTS
5.1. Chapter Overview
5.2. Analysis by Eluted Drug and Administered Drug Concentration (Heat Map)
5.3. Analysis by Eluted Drug and Stent Material (Stacked Bar Chart)
5.4. Analysis by Maximum Stent Length and Maximum Stent Diameter (Tree Map)
5.5. Analysis by Year of Establishment, Company Size, Number of Products Offered and Region (4D Bubble Chart)
5.6. Analysis by Company Size, Region, Number of Products Offered, Maximum Stent Length and Maximum Stent Diameter (Grid Representation)

6. COMPANY COMPETITIVENESS
6.1. Chapter Overview
6.2. Key Assumptions and Parameters
6.3. Methodology
6.3.1. Company Competitiveness Analysis: Small Companies
6.3.2. Company Competitiveness Analysis: Mid-sized Companies
6.3.3. Company Competitiveness Analysis: Large Companies
6.3.4. Company Competitiveness Analysis: Very Large Companies

7. COMPANY PROFILES
7.1. Chapter Overview
7.2. Alvimedica
7.2.1. Company Overview
7.2.2. Novel Cardiovascular Drug Delivery Device Portfolio
7.2.3. Recent Developments and Future Outlook
7.3. B. Braun
7.3.1. Company Overview
7.3.2. Novel Cardiovascular Drug Delivery Device Portfolio
7.3.3. Recent Developments and Future Outlook
7.4. Boston Scientific
7.4.1. Company Overview
7.4.2. Novel Cardiovascular Drug Delivery Device Portfolio
7.4.3. Recent Developments and Future Outlook
7.5 Cook Medical
7.5.1. Company Overview
7.5.2. Novel Cardiovascular Drug Delivery Device Portfolio
7.5.3. Recent Developments and Future Outlook
7.6. Eurocor Scientific
7.6.1. Company Overview
7.6.2. Novel Cardiovascular Drug Delivery Device Portfolio
7.6.3. Recent Developments and Future Outlook
7.7. Lepu Medical
7.7.1. Company Overview
7.7.2. Novel Cardiovascular Drug Delivery Device Portfolio
7.7.3. Recent Developments and Future Outlook
7.8. Medtronic
7.8.1. Company Overview
7.8.2. Novel Cardiovascular Drug Delivery Device Portfolio
7.8.3. Recent Developments and Future Outlook
7.9. Meril
7.9.1. Company Overview
7.9.2. Novel Cardiovascular Drug Delivery Device Portfolio
7.9.3. Recent Developments and Future Outlook
7.10. Relisys
7.10.1. Company Overview
7.10.2. Novel Cardiovascular Drug Delivery Device Portfolio
7.10.3. Recent Developments and Future Outlook
7.11. Sahajanand Medical Technologies
7.11.1. Company Overview
7.11.2. Novel Cardiovascular Drug Delivery Device Portfolio
7.11.3. Recent Developments and Future Outlook

8. PATENT ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Novel Cardiovascular Drug Delivery Devices: Patent Analysis
8.3.1. Analysis by Type of Patent
8.3.2. Analysis by Publication Year
8.3.3. Analysis of Granted Patents by Publication Year
8.3.4. Analysis by Filed Patent by Publication Year
8.3.5. Analysis by Patent Publication Year and Type of Player
8.3.6. Analysis by Issuing Authority
8.3.7. Analysis by Patent Focus
8.3.8. Analysis by Patent Age
8.3.9. Analysis by CPC Symbols
8.3.10. Leading Players: Analysis by Number of Patents
8.3.11. Leading Inventors: Analysis by Number of Patents
8.4. Novel Cardiovascular Drug Delivery Devices: Patent Benchmarking Analysis
8.4.1. Analysis by Patent Characteristics
8.5. Novel Cardiovascular Drug Delivery Devices: Patent Valuation Analysis

9. CASE STUDY: NOVEL CARDIOVASCULAR THERAPEUTICS AND SERVICES / SOLUTIONS
9.1. Chapter Overview
9.2. Novel Cardiovascular Therapeutics: Overall Market Landscape
9.2.1. Novel Cardiovascular Therapeutics Developers: Distribution by Year of Establishment
9.2.2. Novel Cardiovascular Therapeutics Developers: Distribution by Company Size
9.2.3. Novel Cardiovascular Therapeutics Developers: Distribution by Location of Headquarters
9.2.4. Novel Cardiovascular Therapeutics Developers: Distribution by Type of Therapy
9.2.5. Novel Cardiovascular Therapeutics Developers: Distribution by Phase of Development
9.2.6. Novel Cardiovascular Therapeutics: Gene Therapy
9.2.7. Novel Cardiovascular Therapeutics: Next Generation Complement Therapeutics
9.2.8. Novel Cardiovascular Therapeutics: Oral Proteins and Peptides Therapies
9.2.9. Novel Cardiovascular Therapeutics: Regulatory T-cell (Tregs) Therapies
9.2.10. Novel Cardiovascular Therapeutics: Subcutaneous Biologics
9.3. Novel Cardiovascular-based Services / Solutions: Overall Market Landscape
9.3.1. Novel Cardiovascular-based Service Providers: Distribution by Year of Establishment
9.3.2. Novel Cardiovascular-based Service Providers: Distribution by Company Size
9.3.3. Novel Cardiovascular-based Service Providers: Distribution by Location of Headquarters
9.3.4. Novel Cardiovascular-based Service Providers: Distribution by Type of Service
9.3.5. Novel Cardiovascular-based Services: Biopharmaceutical Contract Research Services
9.3.6. Novel Cardiovascular-based Solutions: Digital Therapeutics Solutions
9.3.7. Novel Cardiovascular-based Solutions: Precision Medicine Software

10. DEMAND ANALYSIS
10.1. Chapter Overview
10.2. Key Assumptions and Methodology
10.3. Global Demand for Novel Cardiovascular Drug Delivery Devices, 2022-2035
10.3.1. Analysis by Type of Drug Eluted
10.3.1.1. Global Demand for Sirolimus Eluting Stents
10.3.1.2. Global Demand for Paclitaxel Eluting Stents
10.3.1.3. Global Demand for Everolimus Eluting Stents
10.3.1.4. Global Demand for Zotarolimus Eluting Stents
10.3.1.5. Global Demand for Other Drug Eluting Stents
10.3.2. Analysis by Stent Material
10.3.2.1. Global Demand for Platinum Chromium Stents
10.3.2.2. Global Demand for Cobalt Alloy Stents
10.3.2.3. Global Demand for Stainless Steel Stents
10.3.2.4. Global Demand for Stents Based on Other Materials
10.3.3. Analysis by Geography
10.3.3.1. Demand for Novel Cardiovascular Drug Delivery Devices in North America
10.3.3.1.1. Demand for Novel Cardiovascular Drug Delivery Devices in the US
10.3.3.1.2. Demand for Novel Cardiovascular Drug Delivery Devices in Canada
10.3.3.2. Demand for Novel Cardiovascular Drug Delivery Devices in Europe
10.3.3.2.1. Demand for Novel Cardiovascular Drug Delivery Devices in France
10.3.3.2.2. Demand for Novel Cardiovascular Drug Delivery Devices in Germany
10.3.3.2.3. Demand for Novel Cardiovascular Drug Delivery Devices in Italy
10.3.3.2.4. Demand for Novel Cardiovascular Drug Delivery Devices in the Netherlands
10.3.3.2.5. Demand for Novel Cardiovascular Drug Delivery Devices in Spain
10.3.3.2.6. Demand for Novel Cardiovascular Drug Delivery Devices in the UK
10.3.3.3. Demand for Novel Cardiovascular Drug Delivery Devices in Asia
10.3.3.3.1. Demand for Novel Cardiovascular Drug Delivery Devices in China
10.3.3.3.2. Demand for Novel Cardiovascular Drug Delivery Devices in India
10.3.3.3.3. Demand for Novel Cardiovascular Drug Delivery Devices in Japan
10.3.3.3.4. Demand for Novel Cardiovascular Drug Delivery Devices in South Korea
10.3.3.4. Demand for Novel Cardiovascular Drug Delivery Devices in Middle East and North Africa
10.3.3.4.1. Demand for Novel Cardiovascular Drug Delivery Devices in Israel
10.3.3.4.2. Demand for Novel Cardiovascular Drug Delivery Devices in Turkey
10.3.3.5. Demand for Novel Cardiovascular Drug Delivery Devices in Latin America
10.3.3.5.1. Demand for Novel Cardiovascular Drug Delivery Devices in Brazil
10.3.3.6. Demand for Novel Cardiovascular Drug Delivery Devices in Rest of the World
10.3.3.6.1. Demand for Novel Cardiovascular Drug Delivery Devices in Australia
10.3.3.6.2. Demand for Novel Cardiovascular Drug Delivery Devices in New Zealand

11. MARKET FORECAST
11.1. Chapter Overview
11.2. Key Assumptions and Methodology
11.3. Global Novel Cardiovascular Drug Delivery Devices Market, 2022-2035
11.3.1. Analysis by Type of Drug Eluted
11.3.1.1. Global Sirolimus Eluting Stents Market
11.3.1.2. Global Paclitaxel Eluting Stents Market
11.3.1.3. Global Everolimus Eluting Stents Market
11.3.1.4. Global Zotarolimus Eluting Stents Market
11.3.1.5. Global Other Drug Eluting Stents Market
11.3.2. Analysis by Stent Material
11.3.2.1. Global Platinum Chromium Stents Market
11.3.2.2. Global Cobalt Alloy Stents Market
11.3.2.3. Global Stainless Steel Stents Market
11.3.2.4. Global Market for Stents Based on Other Materials
11.3.3. Analysis by Geography
11.3.3.1. Novel Cardiovascular Drug Delivery Devices Market in North America
11.3.3.1.1. Novel Cardiovascular Drug Delivery Devices Market in the US
11.3.3.1.2. Novel Cardiovascular Drug Delivery Devices Market in Canada
11.3.3.2. Novel Cardiovascular Drug Delivery Devices Market in Europe
11.3.3.2.1. Novel Cardiovascular Drug Delivery Devices Market in France
11.3.3.2.2. Novel Cardiovascular Drug Delivery Devices Market in Germany
11.3.3.2.3. Novel Cardiovascular Drug Delivery Devices Market in Italy
11.3.3.2.4. Novel Cardiovascular Drug Delivery Devices Market in the Netherlands
11.3.3.2.5. Novel Cardiovascular Drug Delivery Devices Market in Spain
11.3.3.2.6. Novel Cardiovascular Drug Delivery Devices Market in the UK
11.3.3.3. Novel Cardiovascular Drug Delivery Devices Market in Asia
11.3.3.3.1. Novel Cardiovascular Drug Delivery Devices Market in China
11.3.3.3.2. Novel Cardiovascular Drug Delivery Devices Market in India
11.3.3.3.3. Novel Cardiovascular Drug Delivery Devices Market in Japan
11.3.3.3.4. Novel Cardiovascular Drug Delivery Devices Market in South Korea
11.3.3.4. Novel Cardiovascular Drug Delivery Devices Market in Middle East and North Africa
11.3.3.4.1. Novel Cardiovascular Drug Delivery Devices Market in Israel
11.3.3.4.2. Novel Cardiovascular Drug Delivery Devices Market in Turkey
11.3.3.5. Novel Cardiovascular Drug Delivery Devices Market in Latin America
11.3.3.5.1. Novel Cardiovascular Drug Delivery Devices Market in Brazil
11.3.3.6. Novel Cardiovascular Drug Delivery Devices Market in Rest of the World
11.3.3.6.1. Novel Cardiovascular Drug Delivery Devices Market in Australia
11.3.3.6.2. Novel Cardiovascular Drug Delivery Devices Market in New Zealand

12. CONCLUSION

13. EXECUTIVE INSIGHTS
13.1. Chapter Overview
13.2. Scitech Medical
13.2.1. Company Snapshot
13.2.2. Interview Transcript: Luciano Curado, Chief Technology Officer
13.3. Translumina
13.3.1. Company Snapshot
13.3.2. Interview Transcript: Harish Rawat, Production Executive

14. APPENDIX I: TABULATED DATA

15. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS